No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALNY240719C250000
- 5.10
- -1.30-20.31%
15min DelayClose Jun 28 16:00 ET
8.00High4.30Low
8.00Open6.40Pre Close95 Volume493 Open Interest250.00Strike Price46.96KTurnover31.58%IV4.98%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry5.10Extrinsic Value100Contract SizeAmericanOptions Type0.3803Delta0.0210Gamma52.83Leverage Ratio-0.1842Theta0.0488Rho20.09Eff Leverage0.2182Vega
Intraday
- 5D
- Daily
News
Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
US MOVERS&SHAKERS Jun 24-Jun 28, 2024
Here are the top 10 gainers and losers of the week.
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Express News | Alnylam Pharmaceuticals Inc : UBS Raises Target Price to $288 From $253
UBS Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $288
UBS analyst Eliana Merle initiates coverage on $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and sets the target price at $288.According to TipRanks data, the analyst has a success rate of 40.
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$2.04 Million in Common Stock
$Alnylam Pharmaceuticals(ALNY.US)$ Director SCHULMAN AMY W sold 8,500 shares of common stock on Jun 25, 2024 at an average price of $240 for a total value of $2.04 million.Source: Announcement What is
Comments
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Substantial insider selling of Alnylam Pharmaceuticals shares over the last quarter, with no recorded purchases, may suggest insiders think shares are not cheap. Insider ownership suggests alignment with shareholder interests, but history of sales warrants caution before buying.
1
Read more